Try our Advanced Search for more refined results

MERCK & CO., INC., SECURITIES, DERIVATIVE & "ERISA" LITIGATION

  1. June 28, 2016

    Judge Signs Off On $1B Deal To End Vioxx Marketing Row

    A New Jersey federal judge on Tuesday granted final approval to a $1.06 billion deal between Merck & Co. Inc. and its investors to resolve multidistrict litigation over the alleged illegal marketing of the painkiller Vioxx, saying the settlement was an "extremely fair and reasonable" conclusion to the long-running case.

  2. May 25, 2016

    Class Attys Want OK Of $1B Deal To End Vioxx Marketing Row

    Class attorneys for Merck & Co. Inc. shareholders that reached a $1.06 billion deal with the pharmaceutical giant to resolve multidistrict litigation over the alleged illegal marketing of Vioxx on Tuesday urged a New Jersey federal court to approve the deal, saying that only 14 individuals and no institutional investors have objected.

  3. May 02, 2016

    Class Attys In Vioxx Case Ask For Approval Of $1B Deal

    Co-lead counsel for Merck & Co. Inc. shareholders that reached a $1.06 billion deal with the pharmaceutical giant to resolve multidistrict litigation over the alleged illegal marketing of the drug Vioxx on Friday asked for court approval of the settlement and more than $9 million in reimbursement fees, detailing the risks that they took during the litigation.

  4. February 11, 2016

    Merck Investors Win Prelim OK Of $1B Vioxx Marketing Deal

    A New Jersey federal judge gave preliminary approval Thursday to Merck's $830 million settlement to resolve multidistrict litigation alleging that the drugmaker defrauded investors by illegally marketing the painkiller Vioxx, a deal that rockets to $1 billion with $232 million in proposed attorneys' fees and expenses.

  5. January 15, 2016

    Merck Pays $830M To End Investor Suit Over Vioxx Marketing

    Merck announced Friday that it will pay $830 million to settle investors' claims in multidistrict litigation accusing the company of committing securities fraud violations by illegally marketing the painkiller Vioxx, after the drugmaker previously agreed to pay a criminal penalty of nearly $1 billion in 2011.

  6. June 19, 2015

    Merck Nixes Some Actions in Vioxx Securities Fraud Battle

    A New Jersey federal judge partially dismissed seven actions Friday within sprawling securities fraud litigation alleging Merck & Co. misrepresented the heart-attack risk of its arthritis drug Vioxx but said some corporate plaintiffs who didn't buy securities still have standing.

  7. May 13, 2015

    Merck Nabs Partial Win In Vioxx Securities Fraud Row

    A New Jersey federal judge ruled Wednesday that a class alleging securities fraud could not prove Merck & Co. Inc. misrepresented Vioxx's heart attack risks at least prior to a study comparing the arthritis medication with another leading drug, but could still prove Merck misled investors after learning of the study results.

  8. March 31, 2015

    Ex-Merck VP Says Investors 'Overstate' Omnicare Impact

    Attorneys for a former Merck & Co. Inc. vice president accused of lying about study results on Vioxx's heart attack link told a New Jersey federal court Tuesday that, contrary to the investors' argument, the U.S. Supreme Court's recent Omnicare ruling actually supports his motion to dismiss the case.

  9. March 26, 2015

    Omnicare Bolsters Case Against Ex-Merck VP, Investors Say

    Shareholders accusing Merck & Co. Inc.'s former vice president of lying about the study results on Vioxx's heart attack link told a New Jersey federal court Wednesday that the U.S. Supreme Court's recent Omnicare ruling "vindicates" their case theory and directly rejects the executive's summary judgment argument.

  10. June 03, 2014

    Ex-Merck VP Says No Proof He Lied About Vioxx Study

    The former vice president of Merck & Co. Inc. has urged a New Jersey federal court to dismiss a securities fraud class action, saying he did not lie to shareholders about the results of a study about painkiller Vioxx being linked to heart attack risks.

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!